IFNγR2 and p300 ablation also attenuated therapy-induced MHC-I (H-2Kq and H-2Dd) surface expression on CD45− cancer cells (Fig. 7L and SI Appendix, Fig. S15 D and E), but had no effect on PD-L1 expression (SI Appendix, Fig. S15F). Here, IFNGR2 is linked to cancer.